MedTrace Logo

Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment

NCT04066322 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-09-24

No results posted yet for this study

Summary

This study is to evaluate the efficacy and tolerability of surgery in selecting patients who can benefit from the synchronous resection of primary pancreatic neuroendocrine tumor and liver metastasis after induction systemic treatment. The willing of participants decide who receive surgery and who will continue to receive standard systemic treatment.

Conditions

Interventions

PROCEDURE

system treatment and surgery

to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.

OTHER

system treatment

to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-25
Primary Completion
2024-07-25
Completion
2025-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066322 on ClinicalTrials.gov